DK532184A - Antigene aminosyresekvenser - Google Patents

Antigene aminosyresekvenser Download PDF

Info

Publication number
DK532184A
DK532184A DK532184A DK532184A DK532184A DK 532184 A DK532184 A DK 532184A DK 532184 A DK532184 A DK 532184A DK 532184 A DK532184 A DK 532184A DK 532184 A DK532184 A DK 532184A
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequences
antigen amino
protein
amino acids
Prior art date
Application number
DK532184A
Other languages
English (en)
Other versions
DK171118B1 (da
DK532184D0 (da
Inventor
Hendrik Mario Geysen
Original Assignee
Commw Serum Lab Commission
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU1984/000038 external-priority patent/WO1984003506A1/en
Application filed by Commw Serum Lab Commission filed Critical Commw Serum Lab Commission
Publication of DK532184A publication Critical patent/DK532184A/da
Publication of DK532184D0 publication Critical patent/DK532184D0/da
Application granted granted Critical
Publication of DK171118B1 publication Critical patent/DK171118B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/222—Foot and mouth disease related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK532184A 1983-03-08 1984-11-08 Syntetisk peptid udvisende den for VP1-proteinet fra mund-og-klovsygevirussen karakteristiske antigenicitet, vaccine samt diagnostisk testsystem omfattende samme DK171118B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPF834783 1983-03-08
AUPF834783 1983-03-08
PCT/AU1984/000038 WO1984003506A1 (en) 1983-03-08 1984-03-08 Antigenically active amino acid sequences
AU8400038 1984-03-08

Publications (3)

Publication Number Publication Date
DK532184A true DK532184A (da) 1984-11-08
DK532184D0 DK532184D0 (da) 1984-11-08
DK171118B1 DK171118B1 (da) 1996-06-17

Family

ID=3770022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK532184A DK171118B1 (da) 1983-03-08 1984-11-08 Syntetisk peptid udvisende den for VP1-proteinet fra mund-og-klovsygevirussen karakteristiske antigenicitet, vaccine samt diagnostisk testsystem omfattende samme

Country Status (5)

Country Link
US (1) US4708871A (da)
EP (1) EP0138854B1 (da)
JP (1) JPS60500673A (da)
CA (1) CA1247080A (da)
DK (1) DK171118B1 (da)

Families Citing this family (369)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DE3813821A1 (de) * 1988-04-22 1989-11-02 Hoechst Ag Synthetische vakzine gegen die maul- und klauenseuche und verfahren zu deren herstellung
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
CA1338800C (en) * 1986-06-17 1996-12-17 Michael Houghton Hepatitis delta and diagnostics and vaccines
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US6730305B1 (en) * 2000-05-08 2004-05-04 The Uab Research Foundation Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins
US5674978A (en) * 1990-09-21 1997-10-07 The Regents Of The University Of California Peptides derived from glutamic acid decarboxylase
DE69130831T2 (de) * 1990-11-21 1999-09-16 Iterex Pharmaceuticals Ltd. Partnership, San Diego Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
US5243540A (en) * 1991-04-03 1993-09-07 The United States Of America As Represented By The Secretary Of The Army Computer-driven amino acid indexer for peptide synthesis
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5919712A (en) * 1993-05-18 1999-07-06 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5512492A (en) * 1993-05-18 1996-04-30 University Of Utah Research Foundation Waveguide immunosensor with coating chemistry providing enhanced sensitivity
US5677196A (en) * 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5480971A (en) * 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5846731A (en) * 1993-06-17 1998-12-08 Torry Pines Institute For Molecular Studies Peralkylated oligopeptide mixtures
US5380668A (en) * 1993-07-06 1995-01-10 University Of Utah Research Foundation Compounds having the antigenicity of hCG
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
US5582997A (en) * 1994-08-24 1996-12-10 Torrey Pines Institute For Molecular Studies Lysine/leucine polypeptides, mixture sets and libraries thereof
US5645996A (en) * 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
US5747458A (en) * 1995-06-07 1998-05-05 Chiron Corporation Urokinase receptor ligands
US5756300A (en) * 1995-11-14 1998-05-26 Research Genetics, Inc. Oligodendrocyte-specific protein and method for diagnosing and treating disease
US6150136A (en) * 1995-11-14 2000-11-21 The Regents Of The University Of California Nucleotide sequence encoding oligodendrocyte-specific protein
EP0961547A4 (en) 1996-08-23 2002-08-14 Univ North Carolina State NEUTRALIZATION SENSITIVE EPITROPE OF CRYPTOSPORIDIUM PARVUM
US6710036B2 (en) 1997-07-25 2004-03-23 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US20040161409A1 (en) * 1997-07-25 2004-08-19 Kurtzman Gary J. Induction of immune response to antigens expressed by recombinant adeno-associated virus
ATE505478T1 (de) 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
RU2000118777A (ru) 1997-12-11 2002-07-10 Университи Оф Саскачеван (Ca) Вирус синдрома мультисистемного истощения свиньи у поросят-отъемышей
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6500637B1 (en) 1998-03-31 2002-12-31 The Institute Of Physical And Chemical Research Neurogenesis inducing genes
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
US20030235594A1 (en) * 1999-09-14 2003-12-25 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
US20040092712A1 (en) * 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
US6656700B2 (en) 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
EP1734050A3 (en) 2000-06-12 2012-12-05 University Of Saskatchewan Immunization of dairy cattle with GapC protein against streptococcus infection
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2001296507A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
US7300659B2 (en) 2001-01-04 2007-11-27 University Of Saskatchewan Enterohemorrhagic Escherichia coli vaccine
EP2338899A1 (en) * 2001-01-18 2011-06-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta PKC
DK1391464T3 (da) 2001-04-27 2008-01-14 Kirin Pharma Kk Anti-CD40 monoklonalt antistof
WO2002099035A2 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633413C (en) 2001-06-20 2012-08-21 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
ATE516042T1 (de) 2001-09-18 2011-07-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2572707A3 (en) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
US8802618B2 (en) * 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2482744C (en) * 2002-05-07 2013-11-26 Chiron Corporation Hiv envelope-cd4 complexes and hybrids
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
EP2047867B1 (en) * 2002-06-19 2013-05-22 Apeiron Biologics AG ACE2 activation for treatment of heart, lung and kidney disease and hypertension
JP2006512901A (ja) * 2002-08-29 2006-04-20 ジェネンテック・インコーポレーテッド Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
EP1923464A1 (en) 2002-08-30 2008-05-21 Japan Science and Technology Agency Ligase of a hyperthermostable bacterium and chip using the same
US7179645B2 (en) * 2002-09-24 2007-02-20 Antigen Express, Inc. Ii-Key/antigenic epitope hybrid peptide vaccines
WO2004030616A2 (en) 2002-09-17 2004-04-15 Antigen Express, Inc. Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
WO2004055167A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
US8034378B2 (en) 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
WO2004096842A2 (en) * 2003-04-28 2004-11-11 Public Health Agency Of Canada Sars virus nucleotide and amino acid sequences and uses thereof
WO2005007808A2 (en) 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
KR100835786B1 (ko) 2003-07-08 2008-06-09 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
NZ547156A (en) * 2003-10-31 2009-08-28 Univ British Columbia Attenuation of A/E pathogen virulence by modulating expression of NleA
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
CA2747871C (en) 2003-11-17 2018-04-10 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
GB0330079D0 (en) * 2003-12-20 2004-02-04 Bioinvent Int Ab Vaccine
US20050267030A1 (en) * 2004-04-30 2005-12-01 Tsao Philip S Use of deltaPKC peptides for modulation of reactive oxygen species
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
CA2569562C (en) * 2004-06-08 2013-12-03 Vega Masignani Fusion proteins comprising cd4 minimal modules and methods of use thereof
JP2008513032A (ja) 2004-09-22 2008-05-01 トリパス イメージング， インコーポレイテッド 乳癌の予後を評価するための方法および組成物
CA2585672A1 (en) 2004-11-01 2006-05-11 Novartis Vaccines And Diagnostics Inc. Combination approaches for generating immune responses
EP2295465B1 (en) 2004-12-06 2013-02-13 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
AU2005321905A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass CD+4 cells in the induction of an immune response
US7563772B2 (en) * 2005-01-04 2009-07-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of increasing cerebral blood flow
ATE471947T1 (de) 2005-02-03 2010-07-15 Novartis Vaccines & Diagnostic Tat-cd4-hiv-hybridmoleküle und verwendungsverfahren dafür
ZA200707490B (en) 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
GB0508726D0 (en) * 2005-04-29 2005-06-08 Bioinvent Int Ab Polypeptide, vaccine and use thereof
AU2006247134B2 (en) 2005-05-18 2012-05-10 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
US7858843B2 (en) 2005-06-06 2010-12-28 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7763460B2 (en) 2005-06-24 2010-07-27 Focus Diagnostics, Inc. Methods and compositions for detecting herpes simplex virus type 2
US8398994B2 (en) 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
US7931902B2 (en) 2005-08-15 2011-04-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP2357000A1 (en) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ES2514316T3 (es) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Partículas similares a virus (VLPs) de Norovirus y Sapovirus
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
CA2631961A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
EP2275130A3 (en) 2005-12-29 2011-03-23 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 immunogenic composition
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
BRPI0707249A2 (pt) 2006-01-27 2011-04-26 Tripath Imaging Inc métodos para identificar pacientes com maior probabilidade de terem cáncer de ovário e composições para os mesmo
EP2050335A1 (en) 2006-02-17 2009-04-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP2009531464A (ja) 2006-03-29 2009-09-03 メリアル リミテッド 連鎖球菌に対するワクチン
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
KR101317235B1 (ko) 2006-04-21 2013-10-15 조마 테크놀로지 리미티드 길항제 항-ｃｄ40 항체 제약 조성물
WO2007134132A2 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
ES2530438T3 (es) 2006-09-12 2015-03-02 Genentech Inc Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
MX2009006066A (es) 2006-12-15 2009-06-17 Boehringer Ingelheim Vetmed Tratamiento de cerdos con el antigeno pcv.
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
BRPI0807635A2 (pt) 2007-02-22 2014-06-03 Genentech Inc Métodos para detecção de doença inflamatória intestinal
WO2008127094A2 (en) 2007-04-12 2008-10-23 Stichting Katholieke Universiteit, More Particularly The Radboud University Nijmegen Medical Center New virulence factors of streptococcus pnuemoniae
WO2008126002A2 (en) * 2007-04-13 2008-10-23 Cytopathfinder, Inc. Compound profiling method
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US8309351B2 (en) * 2007-10-04 2012-11-13 Bionomics Limited Methods of identifying agents that inhibit angiogenesis
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
KR20160129099A (ko) 2007-11-07 2016-11-08 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
CA2705923A1 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
US20090162398A1 (en) * 2007-12-21 2009-06-25 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
JP2011507523A (ja) * 2007-12-21 2011-03-10 ワイス・エルエルシー 遺伝子改変した弱毒化水疱性口内炎ウイルス、組成物およびその使用方法
CA2728347A1 (en) 2008-06-16 2010-01-14 Patrys Limited Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EP2174664A1 (en) 2008-10-07 2010-04-14 Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre New virulence factors of Streptococcus pneumoniae
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
US10338080B2 (en) 2008-12-01 2019-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CA2750922A1 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-key hybrid peptides that modulate the immune response to influenza
EP2403880A1 (en) 2009-03-05 2012-01-11 Tripath Imaging, Inc. Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2403875A1 (en) 2009-03-06 2012-01-11 Tripath Imaging, Inc. Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
RU2016112465A (ru) 2009-08-21 2018-11-27 Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Рекомбинантная вакцина на основе парамиксовирусов птиц и способ её приготовления и применения
AU2010298036B2 (en) 2009-09-25 2015-05-21 Xoma Technology Ltd. Screening methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
KR20120105446A (ko) 2009-10-22 2012-09-25 제넨테크, 인크. 대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
EP2501414B1 (en) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
NZ599707A (en) 2009-11-30 2014-07-25 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2011075379A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
AR079767A1 (es) 2009-12-28 2012-02-15 Merial Ltd Antigeno ndv (virus de la enfermedad de newcastle) recombinante y usos del mismo
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2011112670A2 (en) 2010-03-09 2011-09-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
AU2011224188B2 (en) 2010-03-12 2015-01-22 Boehringer Ingelheim Animal Health USA Inc. Bluetongue virus recombinant vaccines and uses thereof
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
CN103237811A (zh) 2010-05-06 2013-08-07 诺瓦提斯公司 用于治疗性低密度脂蛋白相关蛋白质6(lrp6)多价抗体的组合物及使用方法
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
EP3246044B2 (en) 2010-08-23 2024-04-10 Wyeth LLC Stable formulations of neisseria meningitidis rlp2086 antigens
WO2012030720A1 (en) 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
AU2011346535B2 (en) 2010-12-22 2015-09-24 Wyeth Llc Stable immunogenic compositions of Staphylococcus aureus antigens
US9109231B2 (en) 2011-02-11 2015-08-18 Pioneer Hi Bred International Inc Synthetic insecticidal proteins active against corn rootworm
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US10352936B2 (en) 2011-04-14 2019-07-16 Apoplogic Pharmaceuticals, Inc. Use of tumor Fas expression to determine response to anti-cancer therapy
JPWO2012144546A1 (ja) * 2011-04-22 2014-07-28 ロート製薬株式会社 新規ペプチド
EP2701736A1 (en) 2011-04-25 2014-03-05 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
MX361804B (es) 2011-05-27 2018-12-17 Boehringer Ingelheim Animal Health Usa Inc Vacunas genéticas contra el virus hendra y el virus nipah.
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
JP5925783B2 (ja) 2011-08-12 2016-05-25 国立感染症研究所長 アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
PL2744515T3 (pl) 2011-08-16 2022-05-30 Morphosys Ag Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
SG10201606788VA (en) 2011-08-16 2016-09-29 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
HRP20190525T8 (hr) 2011-11-30 2023-01-20 Boehringer Ingelheim Animal Health USA Inc. Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
ES2758433T3 (es) 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013094720A1 (ja) * 2011-12-22 2013-06-27 ロート製薬株式会社 細胞接着促進能を有する組成物
KR20140119114A (ko) 2012-01-18 2014-10-08 제넨테크, 인크. Fgf19 조절제의 사용 방법
US20130209473A1 (en) 2012-02-11 2013-08-15 Genentech, Inc. R-spondin translocations and methods using the same
CA2864119C (en) 2012-02-14 2022-05-24 Merial Limited Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
CN104203274B (zh) 2012-02-14 2017-09-08 梅里亚股份有限公司 轮状病毒亚单位疫苗及其制备和使用的方法
WO2013129456A1 (ja) * 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104168898A (zh) 2012-03-16 2014-11-26 霍夫曼-拉罗奇有限公司 以pak1抑制剂治疗黑色素瘤的方法
WO2013137920A1 (en) 2012-03-16 2013-09-19 Genentech, Inc. Engineered conformationally-stabilized proteins
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
CN108912215A (zh) 2012-04-02 2018-11-30 北卡罗来纳-查佩尔山大学 用于登革病毒表位的方法和组合物
US9597386B2 (en) 2012-04-05 2017-03-21 Boehringer Ingelheim Vetmedica, Inc. Outer membrane proteins of Histophilus somni and methods thereof
JP6302460B2 (ja) 2012-04-25 2018-03-28 バイオデシー， インコーポレイテッド タンパク質のアロステリックモジュレーターを検出するための方法
EP2848633B1 (en) 2012-05-11 2019-02-06 Microbial Chemistry Research Foundation Anti-cxadr antibody
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
JP6312659B2 (ja) 2012-05-31 2018-04-18 ジェネンテック， インコーポレイテッド Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
ES2664069T3 (es) 2012-06-13 2018-04-18 Merial, Inc. Vacunas contra BTV y AHSV de genoma reordenado
MY173796A (en) 2012-06-27 2020-02-24 Boehringer Ingelheim Animal Health Usa Inc Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2014007402A1 (ja) 2012-07-06 2014-01-09 京都府公立大学法人 眼細胞の分化マーカーおよび分化制御
WO2014014726A1 (en) 2012-07-17 2014-01-23 Merial Limited Attenuated swine influenza vaccines and methods of making and use thereof
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
NZ706288A (en) 2012-08-30 2016-06-24 Merial Inc Expression of chimeric ksac protein and method of producing soluble proteins by high pressure
EP2893008B1 (en) 2012-09-10 2018-07-18 Merial, Inc. Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus ( derzsy's disease)
EP2916863B1 (en) 2012-11-08 2018-05-30 Merial, Inc. Attenuated mannheimia haemolytica vaccines and methods of making and use
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
NZ709289A (en) 2012-12-18 2016-09-30 Asia Pacific Special Nutrients Sdn Bhd High resolution melt genotyping of ndv strains
EP4169929A1 (en) 2012-12-20 2023-04-26 Pfizer Inc. Immunogenic compositions comprising pn-serotype 12f
WO2014121096A1 (en) 2013-02-01 2014-08-07 Auburn University New modified live flavobacterium strains, stabilized vaccines comprising same, and methods of making and use thereof
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
KR20150123250A (ko) 2013-03-06 2015-11-03 제넨테크, 인크. 암 약물 내성의 치료 및 예방 방법
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
WO2014153030A2 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
JP6548631B2 (ja) 2013-03-14 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ドナー特異的抗体を検出する方法及び該方法を実施するためのシステム
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
ES2676023T3 (es) 2013-03-15 2018-07-16 F. Hoffmann-La Roche Ag Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
CN105339001A (zh) 2013-03-15 2016-02-17 基因泰克公司 治疗癌症和预防癌症耐药性的方法
SG10201701380TA (en) 2013-03-15 2017-04-27 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9579373B2 (en) 2013-03-15 2017-02-28 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
BR112015032388A8 (pt) 2013-06-26 2020-01-14 Univ North Carolina Chapel Hill glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições
KR20220042248A (ko) 2013-07-16 2022-04-04 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015048115A1 (en) 2013-09-25 2015-04-02 Zoetis Llc Pcv2b divergent vaccine composition and methods of use
ES2824402T3 (es) 2013-11-01 2021-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas
RU2016128726A (ru) 2013-12-17 2018-01-23 Дженентек, Инк. Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2939416A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
CN107197626B (zh) 2014-03-25 2021-03-02 勃林格殷格翰动物保健美国公司 含有减毒睡眠嗜组织菌的免疫组合物
EP3131584B1 (en) 2014-04-16 2022-01-12 Biocon Limited Stable protein formulations comprising a molar excess of sorbitol
WO2015171523A1 (en) 2014-05-05 2015-11-12 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
WO2015179835A2 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
JP6755235B2 (ja) 2014-07-16 2020-09-16 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 低悪性度漿液性癌におけるｈｅｒ３阻害
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
CN107207619A (zh) 2014-11-02 2017-09-26 北卡罗来纳-查佩尔山大学 用于疫苗及诊断开发的重组登革病毒的方法及组合物
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
EP3227446A1 (en) 2014-12-01 2017-10-11 Novartis AG Compositions and methods for diagnosis and treatment of prostate cancer
US10996222B2 (en) 2014-12-05 2021-05-04 Boehringer Ingelheim Animal Health USA Inc. Enzyme-linked immunosorbent assay (ELISA) for the detection of anti-mycoplasma hyorhinis IgG in swine serum
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3237906B8 (en) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
PT3258960T (pt) 2015-02-20 2021-03-31 Pasteur Institut Proteínas imunoprotetoras de leptospira e métodos de identificação e sua utilização
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
US10376535B2 (en) 2015-03-26 2019-08-13 University Of Rochester Therapy for malignant disease
RU2754661C2 (ru) 2015-05-01 2021-09-06 Дзе Реджентс Оф Дзе Юниверсити Оф Калифорния Гликанзависимые иммунотерапевтические молекулы
PE20180172A1 (es) 2015-05-04 2018-01-22 Pfizer Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
US10881733B2 (en) 2015-05-22 2021-01-05 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
DK3297666T3 (da) 2015-05-22 2019-08-26 Consejo Superior Investigacion Molekylær adjuvans og vaccine
CN107660151B (zh) 2015-05-26 2022-03-11 莫佛塞斯公司 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
WO2016191389A2 (en) 2015-05-27 2016-12-01 Merial, Inc. Compositions containing antimicrobial igy antibodies, for treatment and prevention of disorders and diseases caused by oral health compromising (ohc) microorganisms
PE20180041A1 (es) 2015-06-05 2018-01-09 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
US20180296537A1 (en) 2015-06-05 2018-10-18 Novartis Ag Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
US20180188257A1 (en) 2015-06-19 2018-07-05 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
CA2990643C (en) 2015-06-23 2023-10-17 Merial, Inc. Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
CA2996143A1 (en) 2015-08-20 2017-02-23 Merial, Inc. Fcv recombinant vaccines and uses thereof
MX2018002241A (es) 2015-08-21 2018-03-23 Morphosys Ag Combinaciones y sus usos.
CN108135993B (zh) 2015-08-31 2022-03-22 贝林格尔·英格海姆维特梅迪卡有限公司 用于先天性震颤的瘟病毒疫苗
PT3347377T (pt) 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
PL3355915T3 (pl) 2015-09-29 2024-03-25 Boehringer Ingelheim Animal Health USA Inc. Szczepionki zawierające cząstki wirusopodobne (VLP) parwowirusa psów (CPV) i ich zastosowania
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
EP3371211A4 (en) 2015-11-04 2019-08-21 Icahn School of Medicine at Mount Sinai METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT
US10527613B2 (en) 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
JP2019500025A (ja) 2015-11-18 2019-01-10 オービス ヘルス ソリューションズ エルエルシー Ｔ７アルファウイルスベクター系
RU2714428C2 (ru) 2015-11-23 2020-02-14 Мериал, Инк. Слитые белки fmdv-e2 и их применение
US10188725B2 (en) 2015-12-14 2019-01-29 Elanco Us Inc. Hybrid core feline vaccines
RU2018126297A (ru) 2015-12-18 2020-01-22 Новартис Аг Антитела, нацеленные на cd32b, и способы их применения
CA3048193A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
MA43088B1 (fr) 2016-02-19 2020-10-28 Morphosys Ag Anticorps anti-il-17c
AU2017244108B2 (en) 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
US10485857B2 (en) 2016-04-07 2019-11-26 Boehringer Ingelheim Animal Health USA Inc. Heartworm vaccine, methods and uses thereof
WO2017189730A1 (en) 2016-04-26 2017-11-02 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR20230074823A (ko) 2016-06-27 2023-05-31 모르포시스 아게 항-cd19 항체 제제
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
ES2966699T3 (es) 2016-08-04 2024-04-23 Stichting Amsterdam UMC Marcadores de angiogénesis embrionaria y estrategias diagnósticas y terapéuticas basadas en los mismos
WO2018035199A1 (en) 2016-08-17 2018-02-22 Pharmaq As Sea lice vaccine
EA201990719A1 (ru) 2016-09-20 2019-10-31 Новые промоторы
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv
TW201823467A (zh) 2016-09-20 2018-07-01 德商百靈佳殷格翰維美迪加股份有限公司 犬腺病毒載體
KR102566066B1 (ko) 2016-09-20 2023-08-16 베링거잉겔하임베트메디카게엠베하 신규한 돼지 인플루엔자 백신
PE20191153A1 (es) 2016-09-28 2019-09-05 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos
EP3903821A1 (en) 2016-10-28 2021-11-03 MorphoSys AG Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
EP3535396A1 (en) 2016-11-01 2019-09-11 Novartis AG Methods and compositions for enhancing gene editing
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
WO2018098401A1 (en) 2016-11-23 2018-05-31 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
EP3548078A1 (en) 2016-11-30 2019-10-09 Boehringer Ingelheim Animal Health USA Inc. Attenuated swine influenza vaccines and methods of making and use thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
CA3054167A1 (en) 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
MA49131A (fr) 2017-04-21 2020-03-25 Hoffmann La Roche Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3641752A4 (en) 2017-06-22 2021-03-17 Moonshot Pharma LLC CANCER TREATMENT METHODS USING COMPOSITIONS INCLUDING AMLEXANOX AND IMMUNOMODULATORS
BR112020000711A2 (pt) 2017-07-12 2020-07-14 Boehringer Ingelheim Animal Health USA Inc. composições imunogênicas de senecavírus a e métodos destas
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
US10968258B2 (en) 2017-08-31 2021-04-06 Boehringer Ingelheim Animal Health USA Inc. Streptococcus suis vaccines to protect against reproductive, nursery-age, and growing pig diseases and methods of making and use thereof
UY37889A (es) 2017-09-23 2019-03-29 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresión de paramyxoviridade, antígenos y composiciones inmunogénicas
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
MX2020003562A (es) 2017-10-10 2020-10-01 Numab Therapeutics AG Anticuerpo multiespecifico.
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
EA202091958A1 (ru) 2018-02-23 2021-02-04 Бёрингер Ингельхайм Ветмедика Гмбх Рекомбинантные вирусные векторные системы, экпрессирующие экзогенные гены кошачьего парамиксовируса, и вакцины, приготовленные из них
US11384365B2 (en) 2018-03-19 2022-07-12 Boehringer Ingelheim Vetmedica Gmbh EHV with inactivated UL18 and/or UL8
JP7245260B2 (ja) 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｅｈｖ挿入部位ｕｌ４３
WO2019219765A1 (en) 2018-05-16 2019-11-21 Morphosys Ag Antibodies targeting glycoprotein vi
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
EP3816186A4 (en) 2018-06-29 2022-04-06 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. PD-L1 BINDING POLYPEPTIDE AND USE
WO2020058341A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Intranasal vector vaccine against porcine epidemic diarrhea
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3866832A1 (en) 2018-10-19 2021-08-25 University of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
CA3116334A1 (en) 2018-10-22 2020-04-30 University Of Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein
WO2020140007A1 (en) 2018-12-28 2020-07-02 University Of Rochester Gene therapy for best1 dominant mutations
WO2020150287A1 (en) 2019-01-14 2020-07-23 University Of Rochester Targeted nuclear rna cleavage and polyadenylation with crispr-cas
US20220118089A1 (en) 2019-02-25 2022-04-21 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
WO2020193688A2 (en) 2019-03-27 2020-10-01 Boehringer Ingelheim Vetmedica Gmbh Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
AU2020256283A1 (en) 2019-04-04 2021-11-18 Boehringer lngelheim Vetmedica GMBH Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
CA3144533A1 (en) 2019-06-03 2020-12-10 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
JP7315259B2 (ja) 2019-07-01 2023-07-26 スジョウ・アルファマブ・カンパニー・リミテッド 百日咳毒素結合タンパク質
EP4004206A1 (en) 2019-07-23 2022-06-01 University of Rochester Targeted rna cleavage with crispr-cas
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
CN115175680A (zh) 2019-10-18 2022-10-11 加利福尼亚大学董事会 Plxdc激活剂及其用于治疗血管病症的用途
US20230078498A1 (en) 2020-02-07 2023-03-16 University Of Rochester Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
JP2023514414A (ja) 2020-02-21 2023-04-05 オリジム・バイオテクノロジー・ゲー・エム・ベー・ハー プロピオニバクテリウム・アクネスの予防的かつ治療的な免疫処置
CA3170025A1 (en) 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pvrig binding protein and its medical uses
US20240218367A1 (en) 2020-03-27 2024-07-04 University Of Rochester Targeted Destruction of Viral RNA by CRISPR-Cas13
JP2023519344A (ja) 2020-03-27 2023-05-10 ユニバーシティ オブ ロチェスター ＣＲＩＳＰＲ－Ｃａｓ１３ ｃｒＲＮＡアレイ
US20230167198A1 (en) 2020-04-27 2023-06-01 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
EP4168043A1 (en) 2020-06-17 2023-04-26 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
KR20230035079A (ko) 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질
JP2023534464A (ja) 2020-07-15 2023-08-09 ユニバーシティ オブ ロチェスター ｄＣａｓ１３－ＲＮａｓｅ融合タンパク質による標的ＲＮＡの切断
JP2023534214A (ja) 2020-07-16 2023-08-08 ノバルティス アーゲー 抗ベータセルリン抗体、その断片、及び多重特異性結合分子
EP4186925A1 (en) 2020-07-21 2023-05-31 Suzhou Smartnuclide Biopharmaceutical Co., Ltd. Cd8 binding polypeptide and use thereof
EP4203995A1 (en) 2020-08-26 2023-07-05 Pfizer Inc. Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
EP4046652A1 (en) 2021-02-23 2022-08-24 Johann Wolfgang Goethe-Universität Frankfurt Compositions and methods for diagnosing, treating and preventing carrion's disease
WO2022226296A2 (en) 2021-04-23 2022-10-27 University Of Rochester Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
AU2022289684A1 (en) 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
TW202317644A (zh) 2021-09-15 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 一種含抗ｐｖｒｉｇ／ｔｉｇｉｔ雙特異性抗體的醫藥組成物
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
CN116199782A (zh) 2021-11-30 2023-06-02 苏州康宁杰瑞生物科技有限公司 预防和/或治疗血栓栓塞性疾病的方法
NL2031833B1 (en) 2022-05-11 2023-11-17 Univ Leiden Immunotherapeutic compositions and adjuvants
WO2023240458A1 (zh) * 2022-06-14 2023-12-21 中国医学科学院病原生物学研究所 一种口蹄疫病毒多肽抑制剂及其应用
EP4316513A1 (en) 2022-08-02 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) New dna sars-cov-2 vaccine
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE436645C (sv) * 1976-04-29 1996-07-22 Bonnierfoeretagen Ab Antigeniskt aktiv polypeptid, som kan användas vid cancerdiagnosticering och vid framställning av antikroppar
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ZA824174B (en) * 1981-06-16 1983-04-27 Genentech Inc Production of foot and mouth disease vaccine from microbially expressed antigens thereof
ZA831854B (en) * 1982-03-26 1984-01-25 Biogen Nv Small peptides with the specificity of foot and mouth disease viral antigens
WO1983003547A1 (en) * 1982-04-14 1983-10-27 Bittle, James, L. Synthetic picornavirus antigen
US4544500A (en) * 1982-04-14 1985-10-01 Scripps Clinic And Research Foundation Synthetic foot and mouth disease antigen
US4694071A (en) * 1982-10-11 1987-09-15 National Research Development Corporation Polypeptides useful in vaccination against enteroviruses

Also Published As

Publication number Publication date
EP0138854A4 (en) 1986-04-15
CA1247080A (en) 1988-12-20
DK171118B1 (da) 1996-06-17
JPS60500673A (ja) 1985-05-09
EP0138854A1 (en) 1985-05-02
DK532184D0 (da) 1984-11-08
US4708871A (en) 1987-11-24
EP0138854B1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
DK532184A (da) Antigene aminosyresekvenser
DE3583293D1 (de) Lymphadenopathie-assoziierte huellenantigene und deren verwendungen.
DE69637914D1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
EP0442394A3 (en) Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
ATE171710T1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
DK0491628T3 (da) Lipopeptider inducerende cytotoksiske T-lymfocytter og deres anvendelse som vacciner
DE3685651D1 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
IT1249684B (it) Epitopi della proteina env del virus dell'epatite c.
ATE202114T1 (de) Verwendung von peptiden welche eine immunantwort bewirken zur herstellung von medikamenten zur induzierung der immunsuppression.
DE3886443D1 (de) Menschliche Rhinoviruspeptide.
DE3485972D1 (de) Antigen aktive aminosaeuresequenzen.
DK0426314T3 (da) HIV-relaterede peptider
ATE117319T1 (de) Peptide die vom maul- und klauenseuchevirus stammen.
JP2001517447A5 (da)
FR2760458B1 (fr) Peptide structural antigenique, composes antigenique et immunogene et utilisations dans la detection, la prevention et le traitement d'une infection par le vhc
ATE192163T1 (de) Peptide, analoge und ihre mischungen zur detektion und erzeugung von antikörpern gegen die e1 und e2 proteine des rubella virus
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus
TH4070EX (th) ลำดับ dna ที่มีรหัสของเซอร์เฟสแอนติเจนโปรตีน p31 ที่ดัดแปลงของไวรัสเฮพพาทิทิส บี
TH13622EX (th) ไวรัสที่เสถียรต่อความร้อน
KR950032286A (ko) B형 간염 바이러스에 대한 인체면역 조절기능을 가진 펩타이드

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed